Effects of the Dopamine D2 Allosteric Modulator, PAOPA, on the Expression of GRK2, Arrestin-3, ERK1/2, and on Receptor Internalization

Medicine & Life Sciences

• beta-Arrestin 2 99%
• Piracetam 94%
• 3-(N-prolylamine)-2-oxo-1-pyrrolidineacetamide 86%
• Dopamine 53%
• Schizophrenia 31%
• Dopamine D2 Receptors 30%
• Ligands 27%
• G-Protein-Coupled Receptors 25%
• Rodent Diseases 21%
• Arrestins 20%
• Cyclic GMP-Dependent Protein Kinases 16%
• Corpus Striatum 12%
• Nervous System Diseases 11%
• Pharmaceutical Preparations 10%
• Phosphotransferases 9%
• Binding Sites 9%
• Western Blotting 8%
• Therapeutics 8%
• In Vitro Techniques 5%
• Proteins 4%

Agriculture & Biology

• arrestins 100%
• dopamine 63%
• receptors 43%
• schizophrenia 33%
• ligands 21%
• G-protein coupled receptors 19%
• pathophysiology 19%
• phosphotransferases (kinases) 13%
• nervous system diseases 10%
• disease models 10%
• drugs 10%
• G-proteins 8%
• agonists 7%
• mechanism of action 6%
• binding sites 6%
• rodents 6%
• rats 4%
• proteins 2%
• cells 2%

Chemical Compounds

• Dopamine 59%
• Drug 22%
• Agonist 20%
• Ligand 18%
• Disorder 18%
• Protein 8%
• Molecule 7%